Incyte Seeks FDA approval

Published June 8, 2011 | By AM

By: Zacks Equity Research
June 07, 2011 | Comments: 0
Recommended this article (2)

Recently, Incyte Corporation (INCY – Analyst Report) submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for its lead candidate INCB18424 (ruxolitinib) for treating patients suffering from myelofibrosis (MF), a rare… Continue reading →